The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

This approval marks the eighth disease indication for Dupixent as a new alternative for patients—many of whom are elderly and ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

SNY trades below key moving averages but strong Dupixent growth, pipeline wins and rising estimates may keep bulls invested.

Sanofi and Regeneron's Dupixent is effective in two skin disorders, bullous pemphigoid and chronic spontaneous urticaria. Skip to main content Wednesday 25 June 2025 . BlueSky ...